UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 731

Sortiert nach

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

Diabetes, obesity & metabolism, 2014-01, Vol.16 (1), p.9-21

Madsbad, S.

2014

Link zum Volltext

Verfügbarkeit prüfen

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.500-510

2012

Link zum Volltext

Verfügbarkeit prüfen

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

Diabetes, obesity & metabolism, 2011-05, Vol.13 (5), p.394-407

2011

Link zum Volltext

Verfügbarkeit prüfen

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

Diabetologia, 2002-08, Vol.45 (8), p.1111-1119

2002

Link zum Volltext

Verfügbarkeit prüfen

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

International Journal of Obesity, 2016-11, Vol.40 (11), p.1699-1706

2016

Link zum Volltext

Verfügbarkeit prüfen

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance

American journal of physiology: endocrinology and metabolism, 2012-07, Vol.303 (1), p.E122-E131

2012

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

Diabetologia, 2012-07, Vol.55 (7), p.1890-1901

2012

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2004-11, Vol.351 (19), p.1952-1961

2004

Link zum Volltext

Verfügbarkeit prüfen

Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux‐en‐Y gastric bypass

Neurogastroenterology and motility, 2013-04, Vol.25 (4), p.346-e255

2013

Link zum Volltext

Verfügbarkeit prüfen

Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects

Obesity surgery, 2012-07, Vol.22 (7), p.1084-1096

2012

Link zum Volltext

Verfügbarkeit prüfen

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Diabetologia, 2009-02, Vol.52 (2), p.199-207

2009

Link zum Volltext

Verfügbarkeit prüfen

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass

International Journal of Obesity, 2013-11, Vol.37 (11), p.1452-1459

2013

Link zum Volltext

Verfügbarkeit prüfen

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.74-81

2015

Link zum Volltext

Verfügbarkeit prüfen

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

International Journal of Obesity, 2015-05, Vol.39 (5), p.834-841

2015

Link zum Volltext

Verfügbarkeit prüfen

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Obesity reviews, 2011-08, Vol.12 (8), p.593-601

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.410-418

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review

Diabetic medicine, 2014-11, Vol.31 (11), p.1293-1300

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial

International Journal of Obesity, 2016-02, Vol.40 (2), p.281-290

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial

Osteoporosis international, 2021-09, Vol.32 (9), p.1837-1848

2021

Link zum Volltext

Verfügbarkeit prüfen

Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration

Diabetologia, 2012-02, Vol.55 (2), p.443-449

2012

Link zum Volltext

Verfügbarkeit prüfen

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Diabetic medicine, 2008-09, Vol.25 (9), p.1129-1131

2008

Link zum Volltext

Verfügbarkeit prüfen

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

Diabetologia, 2007-04, Vol.50 (4), p.797-805

2007

Link zum Volltext

Verfügbarkeit prüfen

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial

Osteoporosis international, 2018-11, Vol.29 (11), p.2517-2526

2018

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Diabetic medicine, 2008-02, Vol.25 (2), p.152-156

2008

Link zum Volltext

Verfügbarkeit prüfen

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

International journal of clinical practice (Esher), 2010-01, Vol.64 (2), p.267-276

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 731

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(632)
Mit Volltextzugriff
(586)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(481)
Science & Technology
(465)
Life Sciences & Biomedicine
(457)
Male
(309)
Endocrinology & Metabolism
(291)
Adult
(269)
Female
(256)
Middle Aged
(223)
Biological And Medical Sciences
(185)
Diabetes
(180)
Medical Sciences
(175)
Insulin
(138)
Blood Glucose - Metabolism
(130)
Endocrinopathies
(116)
Glucagon
(112)
Glucose
(112)
Obesity
(106)
Endocrine Pancreas. Apud Cells
(105)
Diabetes. Impaired Glucose Tolerance
(102)
Insulin Resistance
(101)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux‐en‐Y gastric bypass

Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review

Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial

Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial

Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

Suchergebnisse filtern